

Fig. 1

Figure 1. Phase 1 Clinical Trial Study Schema.




Fig. 2

Figure 2. Participant Screening, Treatment and Follow-up Through the Phase 1 Clinical Trial




Fig. 3




Fig. 4**Asterias GRNOPC1****CP35A008 Long Term Follow-up Study****Yearly Telephone Visit: _____****(± 30 Days)**

Subject ID #: _____ **Subject Initials:** _____ **Telephone Visit Date:** _____/_____/_____
DD MMM YYYY

Study Investigator: Please ask the study subject the following questions and document their responses to each question - **Yes or No**. For Yes responses please ask additional follow up questions as needed to obtain the information necessary to make a decision whether to schedule the subject for an in person visit.

1. Have you experienced any changes in your neurological condition during the past 12 months?
 - a. Voluntary muscle movement in your chest, arms, or legs? **Yes** ____ **No** ____
 - i. If Yes, please describe the changes: _____

 - b. Feeling (sensation) in your chest, arms, or legs? **Yes** ____ **No** ____
 - i. If Yes, please describe the changes: _____

 - c. Any other neurological changes? **Yes** ____ **No** ____
 - i. If Yes, please describe the changes: _____

2. If Yes, to questions 1 a – c, was the change documented during a visit with your primary care or treating physician? **Yes** ____ **No** ____
 - a. If Yes, what assessments/tests were done to confirm and document the above changes?
(ISNCSCI Exam/Neurological assessment/MRI and/or CT scan of your level of injury)? _____

 - b. If an MRI and/or CT were done, was there anything wrong with the MRI or CT? _____

 - c. Can a copy of the report and images be requested from your physician and provided to your Asterias study physician for your study records and comparison? **Yes** ____ **No** ____





FIG. 5

SUBSTITUTE SHEET (RULE 26)

FIG. 6






FIG. 7

SUBSTITUTE SHEET (RULE 26)

FIG. 8




FIG. 9





FIG. 10



NBs – Neurobodies - Aggregates post neuroectoderm direct differentiation
EBs – Embryoid Bodies - Aggregates from hESCs without pre aggregates direction

FIG. 11




FIG. 12

